SEC Form 4 · accession 0001209191-18-025198
Regulus Therapeutics Inc. · RGLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kathryn J Collier
Director
Period of report
Apr 14, 2018
Accepted (ET)
Apr 17, 2018 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001505512
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 14, 2018 | A | 60,234 | $0.64 | A | 60,234 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $0.64 | Apr 14, 2018 | A | 110,000 | A | — | Apr 13, 2028 | Common Stock | 110,000 | 110,000 | D |
Explanation of responses
- F1Restricted Stock Units (RSUs) issued in lieu of 2018 annual retainer and committee meeting fees of $38,500. The RSUs vest ratably on a quarterly basis on the last day of each calendar quarter in 2018, subject to the reporting person's continuous service to Regulus.
- F225% of the shares vest on April 14, 2019 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on April 14, 2021, subject to the reporting person's continuous service.